Literature DB >> 2985643

Enzyme-linked immunosorbent assay for determination of antibodies against herpes simplex virus types 1 and 2 in human sera.

B Hampar, M Zweig, S D Showalter, S V Bladen, C W Riggs.   

Abstract

A rapid and reproducible enzyme-linked immunosorbent assay (ELISA) is described for determining antibodies in human sera against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). The sera were absorbed for 30 min with heterologous virus-infected-cell extracts to remove cross-reacting antibodies and then were applied to ELISA plates containing the target antigens, immunoaffinity-purified HSV-1 glycoproteins gC and gD and HSV-2 glycoproteins gD and gF. The absorbance index, defined as the ratio of A414 generated by a serum sample absorbed with a heterologous virus-infected-cell extract versus the A414 of a serum sample absorbed with an uninfected-cell extract, was used to determine the presence or absence of antibodies to HSV-1 and HSV-2. Results of the ELISA for detecting antibodies against HSV-2, when compared with results obtained for the same sera by the microneutralization test, showed an index of overall agreement of 91%. Results of the ELISA for detecting antibodies against HSV-1, when compared with microneutralization test results for sera negative for HSV-2 antibodies but positive for HSV antibodies by ELISA, showed an index of agreement of 99%.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985643      PMCID: PMC271704          DOI: 10.1128/jcm.21.4.496-500.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  Use of the 51 Cr release test to demonstrate patterns of antibody response in humans to herpesvirus types 1 and 2.

Authors:  J W Smith; E Adam; J L Melnick; W E Rawls
Journal:  J Immunol       Date:  1972-09       Impact factor: 5.422

2.  Studies on the relatedness of herpesviruses through DNA-DNA hybridization.

Authors:  H O Ludwig; N Biswal; M Benyesh-Melnick
Journal:  Virology       Date:  1972-07       Impact factor: 3.616

3.  Differentiation between type 1 and type 2 strains of herpes simplex virus by an indirect immunofluorescent technique.

Authors:  L Geder; G R Skinner
Journal:  J Gen Virol       Date:  1971-08       Impact factor: 3.891

4.  The association of genital herpesvirus with cervical atypia and carcinoma in situ.

Authors:  I Royston; L Aurelian
Journal:  Am J Epidemiol       Date:  1970-06       Impact factor: 4.897

5.  Herpesvirus hominis types I and II: a specific microindirect hemagglutination test.

Authors:  D A Fuccillo; F L Moder; L W Catalano; M M Vincent; J L Sever
Journal:  Proc Soc Exp Biol Med       Date:  1970-03

6.  Measurement of antibodies to herpesvirus types 1 and 2 in human sera.

Authors:  W E Rawls; K Iwamoto; E Adam; J L Melnick
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

7.  A serologic study of herpesvirus hominis strains by microneutralization tests.

Authors:  F P Pauls; W R Dowdle
Journal:  J Immunol       Date:  1967-05       Impact factor: 5.422

8.  Association of antigenic type of Herpesvirus hominis with site of viral recovery.

Authors:  W R Dowdle; A J Nahmias; R W Harwell; F P Pauls
Journal:  J Immunol       Date:  1967-11       Impact factor: 5.422

9.  Comparison of a screening test and a reference test in epidemiologic studies. I. Indices of agreement and their relation to prevalence.

Authors:  A A Buck; J J Gart
Journal:  Am J Epidemiol       Date:  1966-05       Impact factor: 4.897

10.  Herpesvirus type 2: association with carcinoma of the cervix.

Authors:  W E Rawls; W A Tompkins; M E Figueroa; J L Melnick
Journal:  Science       Date:  1968-09-20       Impact factor: 47.728

View more
  1 in total

1.  Flow cytometric indirect immunofluorescence assay with high sensitivity and specificity for the detection of antibodies to HSV-1 and HSV-2.

Authors:  A Caruso; M Tinti; L Peroni; E Cabibbo; C De Rango; N Manca; A Turano
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.